<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Clinical Science at South Bristol</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/36B27542-B6C5-4F28-8E59-154E251C6B30"><gtr:id>36B27542-B6C5-4F28-8E59-154E251C6B30</gtr:id><gtr:firstName>Sarah</gtr:firstName><gtr:otherNames>Kate</gtr:otherNames><gtr:surname>Westbury</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK023489%2F1"><gtr:id>EBE30E1B-2E2F-4583-9D09-D5AA9CDF62BC</gtr:id><gtr:title>MECHANISMS IN HAEMOPOIETIC DIFFERENTIATION: INSIGHTS FROM NOVEL LOCI IN GENETIC THROMBOCYTOPENIA</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/K023489/1</gtr:grantReference><gtr:abstractText>My overall research objective is to improve understanding of how specialised cells in sites such as the blood or blood vessels develop from stem cells. This knowledge is essential for new stem cell treatments for common illnesses such as heart disease and cancer. My research will focus on how stem cells develop into blood platelets. However, my research findings will be applicable to other cell types, particularly other blood cells and cells that form new blood vessels. 

Platelets are cell-like components of blood that are made in the bone marrow by the process of differentiation, in which stem cells develop into progressively more specialised cell types. The final cell in this pathway is the megakaryocyte which then fragments to form platelets. Platelet formation is controlled by many proteins, each of which is made from a different gene. It is not fully understood which proteins and genes are involved in platelet formation, or how these are regulated.

The principle behind my research is that people with naturally occurring faults in genes involved in platelet formation will have reduced numbers of platelets in the blood (thrombocytopenia). Therefore, I will carefully select study subjects with thrombocytopenia of likely genetic cause, search for new genetic faults and then test experimentally how these affect platelet formation. This strategy enabled my co-supervisor Prof Ouwehand and others to discover that faults in the RBM8A and NBEAL2 genes cause the rare Gray Platelet and Thrombocytopenia Absent Radii syndromes in which platelet formation is reduced. This research also clarified how these genes control normal platelet formation. 

I will extend the search for faulty genes that cause thrombocytopaenia by identifying study subjects with low platelet counts from two sources: 1) patients with severe thrombocytopenia causing bleeding registered at Haemophilia centres in SW England; and, 2) women from antenatal clinics in Bristol, Oxford and Cambridge with mild thrombocytopenia, detected on routine antenatal blood tests. In this group, non-genetic causes of thrombocytopenia are common. However, I will use additional blood tests and expert input from obstetric haematologists to help identify women with a high likelihood of genetic thrombocytopenia. 

With help from the NIHR-BioResource centre for rare diseases, I will invite participants to give DNA samples for analysis at The Wellcome Trust Sanger Institute. I will use 'next generation sequencing' technology to look at the DNA sequence in all human genes that make proteins (ExoSeq) and some DNA sequences that regulate these genes. I will link my results with the Europe-wide BRIGDE study (co-ordinated by Prof Ouwehand) which will provide Exoseq results from 1000 patients with bleeding disorders, including some with genetic thrombocytopenia. This will help confirm that gene faults identified in the study subjects are the cause of thrombocytopenia.

I will spend most of my research study investigating the precise role of one new faulty gene in platelet formation. This will involve several state-of-the-art laboratory techniques developed by my supervisors and collaborators, including detailed re-analysis of blood cells from selected study participants. I will analyse the effect of 'switching off' the gene in well-tested model systems and in stem cells purified from blood samples and differentiated in the laboratory to form megakaryocytes and other cells. I will identify how the protein made from the gene interacts with other proteins. 

My research will reveal new genes that are important for platelet production. It will also identify the precise role of one new gene in how stem cells differentiate to form platelets and other specialised cells. These findings will have broader relevance to stem cell biology and will assist development of cellular regenerative therapies for common disorders.</gtr:abstractText><gtr:technicalSummary>1. Recruitment of index cases
I will recruit patients at SW England haemophilia centres if their registration diagnosis is genetic thrombocytopenia. I will also identify women from obstetric haematology clinics if their platelet (PLT) count is &amp;lt;80x10^9/dL at booking and at all subsequent tests in pregnancy. I will exclude women if any PLT count outside pregnancy is within reference interval or if acquired thrombocytopenia is detected using a pre-specified test panel (eg. autoantibody screen, lupus anticoagulant). I will invite eligible women to participate only with further evidence of genetic thrombocytopenia (eg. family history, high PLT volume). After informed consent, the Cambridge BioResource for Rare Diseases will collect demographic and clinical phenotype data and will store DNA samples. 

2. Identification of novel loci 
I will exo-seq DNA using the Roche/Nimblegen SeqCap EZ Human Exome Library v3.0 which covers &amp;gt;98% of 198,334 exons in the 64Mb CCDS regions gene set, expanded by 32Mb to capture most annotated regulatory elements in megakaryocytes. Exo-seq will be at the Eastern Sequence and Informatics Hub using Illumina-HiSeq analysers. I will work with the MRC Biostatistics Unit to identify causative variations using the UK10K and other resources to eliminate non-pathogenic common variations. Based on pilot studies for GPS and TAR, significant genome-wide P values of association were observed with exo-seq results of 10 cases only. The power of my sample of 150 to identify a novel locus will be enhanced by data sharing with the BRIDGE exo-seq programme of 1000 cases which is sufficiently powered to yield several new loci and will increase case finding for each locus.

3. Functional analysis of a locus
I will perform deep phenotyping of index cases, gene knockdown and phenotyping in zebrafish and gene knockdown and TALEN-modification of iPSC using protocols developed by my collaborators in Cambridge and Bristol.</gtr:technicalSummary><gtr:potentialImpactText>The multiple academic beneficiaries from this research and how they will benefit is described above in 'academic beneficiaries'. This research will also impact on several other groups of non-academic beneficiaries: 

1. Study participants (1-2 years):
Participants in the clinical component of my research will benefit directly through feedback of the results of genetic testing. In most cases this expected to be a definitive or provisional genetic diagnosis accompanied by further phenotypic and prognostic information obtained by data sharing within the BRIDGE study consortium. Identification of causative nucleotide variations in study participants informs genetic counselling of family members, and potentially enables interventions such as antenatal diagnosis. 

2. Other patients with thrombocytopenia (2-3 years):
Thrombocytopenia is a common clinical finding that may be associated with significant morbidity through bleeding. However, genetic thrombocytopenia often cannot be distinguished from acquired disorders such as autoimmune thrombocytopenia using phenotypic tests. This distinction is critical because genetic thrombocytopenia may indicate that family members, such as unborn babies, are at increased risk of bleeding. Immunosuppressive treatments to improve platelet counts are inappropriate in genetic thrombocytopenia. 

This research will improve diagnostic pathways for thrombocytopenia for patients at haemophilia centres and obstetric haematology clinics where issues such as bleeding risk and heritability are critical. This has wider applicability to other patient groups where diagnosis of thrombocytopenia is important. 

3. Patients with cardiovascular, malignant and metabolic disease (5-10 years):
The major impact of my research will be from increased mechanistic understanding of how precursor stem cells differentiate into committed haemopoietic and cardiovascular cells. This is directly relevant to cellular regenerative therapies in cardiovascular disease and malignancy. Therefore, the indirect beneficiaries of this research will be patients with common disorders such as bone marrow failure after chemo- and radiotherapy for malignant disease and those with cardiac failure in ischaemic heart disease. 

The main focus of my research is megakaryocyte differentiation and will involve gene manipulation in this cell. Megakaryocytes are an attractive vehicle for new gene-delivery therapies for haematological and metabolic disorders (Shi, Q Adv Drug Deliv Rev. 2010). Therefore, my research also offers potential long-term benefits to patient groups with these disorders.</gtr:potentialImpactText><gtr:fund><gtr:end>2017-11-22</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-08-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>198112</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>86AD9CDC-A9EB-4637-A467-F3C00E371086</gtr:id><gtr:title>Phenotypic Characterization ofMutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01c5e945aa307d1ad0be78b05f4d2293"><gtr:id>01c5e945aa307d1ad0be78b05f4d2293</gtr:id><gtr:otherNames>Hadinnapola C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn><gtr:outcomeId>5a855cc3192b08.50636125</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8159CE10-6AF4-4A41-A3A2-C99EF109F00A</gtr:id><gtr:title>Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a11d973ca4f3b4064143824a7f4f8344"><gtr:id>a11d973ca4f3b4064143824a7f4f8344</gtr:id><gtr:otherNames>Farmery JHR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a855cc2cd9f26.74631551</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26BA514A-1FA2-43E8-980F-1E45DC233E91</gtr:id><gtr:title>TUBB1 variants and human platelet traits.</gtr:title><gtr:parentPublicationTitle>Platelets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cbba03ad0f9dee9cf1d19a60be61106"><gtr:id>5cbba03ad0f9dee9cf1d19a60be61106</gtr:id><gtr:otherNames>Burley K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0953-7104</gtr:issn><gtr:outcomeId>5a855c5a51d9e8.65804285</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>378960C4-C945-4A4B-836B-DD3A65A6F1BC</gtr:id><gtr:title>Genomics of platelet disorders.</gtr:title><gtr:parentPublicationTitle>Haemophilia : the official journal of the World Federation of Hemophilia</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69882978360f01969a69f359e9dff0d8"><gtr:id>69882978360f01969a69f359e9dff0d8</gtr:id><gtr:otherNames>Westbury SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1351-8216</gtr:issn><gtr:outcomeId>585d39ae274639.79076709</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A67E301C-7766-43F0-B0B3-C0214B4307EB</gtr:id><gtr:title>A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4c0e2c4fe4e41d2c3b636d3d1674780"><gtr:id>e4c0e2c4fe4e41d2c3b636d3d1674780</gtr:id><gtr:otherNames>Turro E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn><gtr:outcomeId>56dd727d5342d7.79808786</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF3352F1-2214-489C-861C-6DDE52F43281</gtr:id><gtr:title>ACTN1 variants associated with thrombocytopenia.</gtr:title><gtr:parentPublicationTitle>Platelets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69882978360f01969a69f359e9dff0d8"><gtr:id>69882978360f01969a69f359e9dff0d8</gtr:id><gtr:otherNames>Westbury SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0953-7104</gtr:issn><gtr:outcomeId>5a2fd62b693863.54674080</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1C44D158-9D4A-43D3-8EA3-8A48756659F1</gtr:id><gtr:title>Protease-Activated Receptor 4 Variant p.Tyr157Cys Reduces Platelet Functional Responses and Alters Receptor Trafficking.</gtr:title><gtr:parentPublicationTitle>Arteriosclerosis, thrombosis, and vascular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15baee59240e9c8b3a9b71289ebf646b"><gtr:id>15baee59240e9c8b3a9b71289ebf646b</gtr:id><gtr:otherNames>Norman JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1079-5642</gtr:issn><gtr:outcomeId>585d717b0b98a0.70912480</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5569E659-1F0B-45D1-ACE9-A4C958D8318B</gtr:id><gtr:title>Abstracts of papers presented at the 1Italian-UK Platelet Meeting University of Bath, 7-8 September 2017.</gtr:title><gtr:parentPublicationTitle>Platelets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/173ec3056fbd6fe9bc7f45141783bab5"><gtr:id>173ec3056fbd6fe9bc7f45141783bab5</gtr:id><gtr:otherNames>Pula G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0953-7104</gtr:issn><gtr:outcomeId>5a8560d18e9098.23921512</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>886D452A-546B-4E62-9773-482FD73D06DD</gtr:id><gtr:title>Rare variants in GP1BB are responsible for autosomal dominant macrothrombocytopenia.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/edec38ae83d4017f0984375e6bd63947"><gtr:id>edec38ae83d4017f0984375e6bd63947</gtr:id><gtr:otherNames>Sivapalaratnam S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>58b5ab91c76f32.65752368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF9AC971-A357-4A9A-9457-9FAAA8B54529</gtr:id><gtr:title>Expanded repertoire ofvariants responsible for platelet dysfunction and severe bleeding.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69882978360f01969a69f359e9dff0d8"><gtr:id>69882978360f01969a69f359e9dff0d8</gtr:id><gtr:otherNames>Westbury SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>5a6d7ea1e413e1.21523262</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E97E04EB-890E-4403-A29B-7D30AEDBC2A7</gtr:id><gtr:title>How should we test for nonsevere heritable platelet function disorders?</gtr:title><gtr:parentPublicationTitle>International journal of laboratory hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15baee59240e9c8b3a9b71289ebf646b"><gtr:id>15baee59240e9c8b3a9b71289ebf646b</gtr:id><gtr:otherNames>Norman JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1751-5521</gtr:issn><gtr:outcomeId>544fca1b4b49f3.34817140</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41E949EA-74CF-44C7-8A21-AEB10B0C47B1</gtr:id><gtr:title>A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c47ae7bd327b69471dbc4a455119a6f"><gtr:id>0c47ae7bd327b69471dbc4a455119a6f</gtr:id><gtr:otherNames>Simeoni I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>58b5abdde2fc22.86926805</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A00EFC2D-F9BC-44E1-A3A5-D9B0035F8CEA</gtr:id><gtr:title>Altered fibrinolysis in autosomal dominant thrombomodulin-associated coagulopathy.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cbba03ad0f9dee9cf1d19a60be61106"><gtr:id>5cbba03ad0f9dee9cf1d19a60be61106</gtr:id><gtr:otherNames>Burley K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>58b5ab920e86e7.32479507</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E99BF3FF-B614-4599-8C5D-5E7C8674D631</gtr:id><gtr:title>Transcriptional diversity during lineage commitment of human blood progenitors.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fbfd9fb6e692d07596464ca94848bf67"><gtr:id>fbfd9fb6e692d07596464ca94848bf67</gtr:id><gtr:otherNames>Chen L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn><gtr:outcomeId>544fca1b82cae4.05447964</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>24AB4D94-7926-4749-9071-8669D20008BE</gtr:id><gtr:title>Mutations in tropomyosin 4 underlie a rare form of human macrothrombocytopenia.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4cb8e53e6fea991d93e847f38e5c9e2b"><gtr:id>4cb8e53e6fea991d93e847f38e5c9e2b</gtr:id><gtr:otherNames>Pleines I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>58b5ab91a32ff3.58612288</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C939B4D-F079-4CDB-9E1F-3753ED30D6D9</gtr:id><gtr:title>aIIb?3 variants defined by next-generation sequencing: predicting variants likely to cause Glanzmann thrombasthenia.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4741579f0d4ece1bd30d4246ad227a11"><gtr:id>4741579f0d4ece1bd30d4246ad227a11</gtr:id><gtr:otherNames>Buitrago L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>56d5b7c9ec6395.45226481</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC409F41-6F8E-43F5-8162-A7BED046FB76</gtr:id><gtr:title>Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders.</gtr:title><gtr:parentPublicationTitle>Genome medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69882978360f01969a69f359e9dff0d8"><gtr:id>69882978360f01969a69f359e9dff0d8</gtr:id><gtr:otherNames>Westbury SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1756-994X</gtr:issn><gtr:outcomeId>5675e3ea838b3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB6403B7-852E-4BAA-9C90-16DDF83F7982</gtr:id><gtr:title>A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ad517b46218a425c2709298b75184e34"><gtr:id>ad517b46218a425c2709298b75184e34</gtr:id><gtr:otherNames>Stritt S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>56d59f025462a8.29716654</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40C8537D-98D0-4D52-AA5C-611EEF960D42</gtr:id><gtr:title>Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61711e17c223459294a27a3946aed64a"><gtr:id>61711e17c223459294a27a3946aed64a</gtr:id><gtr:otherNames>Carss KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>58b5ac7fa08c97.02950244</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>368DEBC2-EB98-4E8C-A202-6FC869D81254</gtr:id><gtr:title>Biallelic Mutation of ARHGEF18, Involved in the Determination of Epithelial Apicobasal Polarity, Causes Adult-Onset Retinal Degeneration.</gtr:title><gtr:parentPublicationTitle>American journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88f016512e3e841e2f352e85bc2a6c1d"><gtr:id>88f016512e3e841e2f352e85bc2a6c1d</gtr:id><gtr:otherNames>Arno G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-9297</gtr:issn><gtr:outcomeId>5a855cc3908b42.03794811</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K023489/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>939798CA-B6AE-4C12-9DCC-A0F88F84E6F3</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Blood</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>